Annegret de Baey-Diepolder

Annegret de Baey-Diepolder is an experienced professional in the life sciences sector, currently serving as a Member of the Board of Directors for Cytoki Pharma, Abalos Therapeutics GmbH, and Dopavision GmbH. Since April 2017, Annegret has been a Venture Partner at Seventure Partners, and from November 2011, Annegret has been providing interim management and consulting services through de Baey Science to Business Consulting. Additional past roles include Board Observer at Tubulis GmbH, Board Member at Humedics GmbH, Interim CEO at Ugichem Gesellschaft Für Organische Chemie mbH, and CEO at both Rigontec GmbH and ImmunOligo GmbH. Annegret holds a Medical Doctor degree specializing in Dermatology, Allergology, and Immunology from the Technical University of Munich.